A STUDY OF CMC , POST APPROVAL REGULATORY AFFAIRS
Abstract
Chemistry, Manufacturing and Controls (CMC) is a critical component of regulatory submissions that ensures the quality, safety, and efficacy of pharmaceutical products. Post-approval CMC activities focus on managing changes after a drug product has received marketing authorization. These changes may occur in raw materials, manufacturing processes, equipment, facilities, or analytical methods. Regulatory authorities require that all post-approval changes are properly evaluated, documented, and reported .The main objective of post-approval CMC is to maintain consistent product quality throughout the product lifecycle .Any modification should not adversely affect the identity, strength, quality, purity, or potency of the drug product.Post-approval changes are classified based on their potential impact on product quality.Common categories include minor, moderate, and major changes.Different regulatory pathways are followed depending on the risk level of the change.Regulatory agencies such as US FDA, EMA, and CDSCO provide guidelines for post-approval CMC changes.In the US, changes are reported through supplements like PAS, CBE-30, or annual reports.Stability studies play an important role in supporting post-approval changes.Validation and re-validation of processes are often required after significant changes.Change control systems ensure proper evaluation and approval of modifications.Post-approval CMC documentation includes updated specifications, batch records, and validation reports.Continuous monitoring of manufacturing processes is essential for compliance.Quality Risk Management (QRM) tools are applied to assess the impact of changes.Post-approval CMC activities support product lifecycle management.They also help in scale-up, site transfer, and technology transfer.Regulatory compliance during post-approval ensures uninterrupted product supply.Failure to report changes may lead to regulatory action.Post-approval inspections verify compliance with approved CMC information.Good Manufacturing Practices (GMP) must be maintained at all times.Post-approval CMC ensures patient safety and product reliability.It supports continuous improvement without compromising quality.Effective communication with regulatory authorities is essential.CMC post-approval is a dynamic and ongoing regulatory process.
Downloads
References
2. The Pharmaceutical Regulatory Process, Edited by Ira R. Berry and Robert P. Martin, Drugs and the Pharmaceutical Sciences,Vol.185, Informa Health care Publishers.
3. New Drug Approval Process: Accelerating Global Registrations by Richard A Guarino, MD,Drugs and the Pharmaceutical Sciences, Vol.190.
4. Guidebook for drug regulatory submissions / Sandy Weinberg. By John Wiley & Sons.Inc.
5. FDA regulatory affairs: a guide for prescription drugs, medical devices, and biologics/editedBy Douglas J. Pisano, David Mantus.
6. Clinical Trials and Human Research: A Practical Guide to Regulatory Compliance By Fay A.Rozovsky and Rodney K. Adams
7. www.ich.org/
8. www.fda.gov/
9. europa.eu/index_en.htm
10. https://www.tga.gov.au/tga-basics
11. World Health Organization (WHO). WHO Technical Report Series: Good Manufacturing Practices.
12. ICH Q1A(R2). Stability Testing of New Drug Substances and Products.
13. ICH Q3A(R2). Impurities in New Drug Substances.
14. ICH Q3B(R2). Impurities in New Drug Products.
15. ICH Q6A. Specifications: Test Procedures and Acceptance Criteria.
16. ICH Q7. Good Manufacturing Practice for Active Pharmaceutical Ingredients.
17. ICH Q8(R2). Pharmaceutical Development.
18. ICH Q9. Quality Risk Management.
19. ICH Q10. Pharmaceutical Quality System.
20. ICH Q11. Development and Manufacture of Drug Substances.
21. US FDA. Code of Federal Regulations (21 CFR Parts 210 & 211).
22. US FDA. Guidance for Industry: NDA and ANDA Submissions.
23. US FDA. CMC Review Manual.
24. US FDA. Post-Approval Changes (SUPAC) Guidelines.
25. EMA. Guideline on Process Validation.
26. EMA. Guideline on Quality of Finished Products.
27. EMA. Variation Classification Guideline.
28. EMA. ICH Guidelines Implementation in EU.
29. European Commission. EudraLex – Volume 4 (EU GMP Guidelines).
30. European Commission. EudraLex – Volume 2A: Marketing Authorization.
31. CDSCO (India). Drugs and Cosmetics Act, 1940.
32. CDSCO (India). Drugs and Cosmetics Rules, 1945.
33. CDSCO. Guidance Document for Industry on CTD Format.
34. Schedule M. Good Manufacturing Practices (India).
35. Indian Pharmacopoeia Commission. Indian Pharmacopoeia.
36. United States Pharmacopeia (USP–NF).
37. British Pharmacopoeia (BP).
38. Japanese Pharmacopoeia (JP).
39. Lachman L., Lieberman H.A., Kanig J.L. The Theory and Practice of Industrial Pharmacy.
40. Berry I.R., Martin R.P. Pharmaceutical Regulatory Affairs.
41. Gupta P.K. Drug Regulatory Affairs.
42. Bentley’s. Textbook of Pharmaceutics.
43. Remington. The Science and Practice of Pharmacy.
44. Allen L.V. Pharmaceutical Calculations.
45. FDA. Guidance on Process Validation: General Principles and Practices.
46. FDA. Data Integrity and Compliance with CGMP.
47. ICH M4. Common Technical Document (CTD).
48. WHO. Guidelines on Submission of Documentation for Multisource Products.
49. EMA. Post-Approval Change Management Protocol.
50. FDA & EMA. Guidelines on Lifecycle Management of Pharmaceuticals.
Copyright (c) 2026 IJRDO - JOURNAL OF BIOLOGICAL SCIENCE
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the IJRDO Journal will have the full right to remove the published article on any misconduct found in the published article.
